to increased intrathoracic pressure and central venous pressure, decreased venous return from the brain and increased ICP [4] • Patients with aneurysmal SAH have disturbed autoregulation of cerebral blood flow. Hence, intraoperative hypotension of any cause has an adverse effect on the outcome of SAH [5, 6] • Patients with poor grade SAH (Fischer III/IV) and angiographic evidence of vasospasm which our patient had, are at risk for cerebral hypoperfusion because of impaired cerebral autoregulation and thus intraoperative hypotension and cerebral hypoperfusion compounds the poor outcome [6, 7] • Blood loss leading to severe anaemia (Hb 3.8 g%)
during the procedure might have lead to decreased oxygen-carrying capacity of blood and further exacerbate the hypoxic injury to brain.
Thus a combination of age, poor grade SAH, diffuse atherosclerosis, pre-existing vasospasm, raised intra-abdominal pressure leading to raised ICP, severe anaemia and delayed diagnosis and management of perforated iliac artery injury lead to poor clinical outcome in our patient.
This case demonstrates that possibility of catastrophic vascular perforation with intra-abdominal haematoma although rare, must be considered during INR procedures when severe hypotension unresponsive to fluid management develops during the procedure. The combination of severe hypotension with elevated intra-abdominal pressure in poor grade SAH can have deleterious effect on intracranial compliance leading to poor neurological outcome in patients with sub-arachnoid haemorrhage and pre-existing vasospasm. Thus, the anaesthesiologist must be aware of this complication and should anticipate and inform the interventional radiologist regarding vascular injury when there is refractory hypotension so that necessary steps can be taken to identify and treat iatrogenic complications that might compound the pre-existing morbidity.
of craniopharangioma. He was apparently well 2 months back when he had progressive decrease in vision (right > left). He was not able to visualize on lateral vision, and his right side pupil was not reacting to light. He got operated for the same and was shifted for elective ventilation. On 1 st postoperative day, his trachea was extubated as computerized tomography (CT) scan was normal. One week after surgery, he suddenly became drowsy. On investigation, there was electrolyte imbalance (Na + -116 mEq/L, K + -2.7 mEq/L). He was started on 3% NaCl infusion along with KCl supplement.
hyponatraemia from January 2009 through November 2010. Regardless of whether the patient was euvolemic or hypervolemic, no significant difference was noted in serum sodium concentration after initiation of treatment or in frequency of over-correction between groups. [3] However, conivaptan given as a bolus can effectively treat acute hyponatraemia in brain-injured patients. [4] Efficacy of vaptans is now well-accepted for management of hyponatraemia over a short period. However, vaptans have not become the mainstay treatment of hyponatraemia yet. [5] Whereas conivaptan is to be administered intravenously, the other vaptans such as tolvaptan, lixivaptan and satavaptan are effective as oral medication.
Tolvaptan is approved for treatment of clinically significant hypervolemic/euvolemic hyponatraemiaserum sodium <125 mEq/L or less marked symptomatic hyponatraemia that has resisted correction with fluid restriction-but not heart failure without hyponatraemia. [6] Conivaptan is a nonspecific arginine vasopressin receptor antagonist that has been used as therapy in adults who have hypervolemic hyponatraemia due to congestive heart failure. [7] Intravenous conivaptan is effective for increasing serum sodium levels and may be a potential adjuvant to enhance diuresis in children with cardiac disease. [8] Further studies are required before conivaptan can be recommended for routine use in children.
However, conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. No dose adjustment is necessary in patients with mild or moderate renal impairment and in patients with mild hepatic impairment. [9] No data are available on the use of vaptans in acute hyponatraemia, and they are not indicated in hypovolemic hyponatraemia. [10] However, there are case reports where an extremely rapid correction of serum sodium with a typical dosing regimen of conivaptan were seen. [11] Vasopressin-receptor antagonists, by reversing osmotic shifts, may be novel agents to control ICP and cerebral edema, especially in the setting of falling sodium. [12] The one of the possible cause of sudden neurological deterioration in this patient was diabetes insipidus which was ruled out by hourly urine output measurement that was within normal range as was the urine specific gravity. His volume status, adequately measured by central venous pressure, was also in normal limits. The intracranial bleed or infarction was also ruled out by doing a repeat CT scan was normal.
There was no specific indication to start the conivaptan infusion in our patient as he was responding well to the treatment with hypertonic saline. The infusion was started after receiving the instructions from the neurosurgeon as he wanted to see the response of this drug and the infusion of conivaptan was started without consulting the anaesthesiologist on duty. Through this
The electrolyte levels improved gradually over a period of 1 day (Na + -120 mEq/L, K + -3.6 mEq/L) along with improvement in his general condition. Two days later, infusion of the injection conivaptan was started by a nursing staff in the presence of a neurosurgeon and was further monitored by the anaesthesiologist on duty in the Neuro-ICU. He was started on injection conivaptan infusion 20 mg IV over 30 minutes followed by 20 mg IV over 24 h. At the starting point of infusion, the serum sodium level was 123 mEq/lt. Subsequent ABG picture showed rapid rise in Na + level within 20 minutes (Na + -153 mEq/L, K + -5.5 mEq/L). Within that duration, he became drowsy, irritable and disoriented; therefore, the trachea was intubated to secure the airway. His hourly urine output was 150-200 ml/h, and urine specific gravity remained between 1007-1008. The central venous pressure was also measured, and it was within normal range (9-10 cmH 2 O). A repeat CT scan was performed to rule out any intracranial bleed or infarction, and the findings were non-significant.
Electrolyte abnormalities are linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatraemia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatraemia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. [1] Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). It inhibits two of the three subtypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus. It is given as loading dose 20 mg IV infusion over 30 minutes and then 20 mg IV as continuous infusion over a 24-h period for 2-4 days. After initial day of treatment, it may be increased to 40 mg/day if necessary. Monitor serum sodium and volume status frequently; a significant increase in serum sodium (>12 mEq/L/24 h) may result in serious neurologic effects. Vaptans can be considered a new effective tool for the treatment of euvolemic and hypervolemic hyponatraemia. Nevertheless, more comparative research of vaptans versus other therapies on clinical grounds is needed to more accurately assess the value of these drugs in the treatment of hyponatraemia. [2] The single-centre retrospective study from The Methodist Hospital (TMH) compared the effect of hypertonic saline (HS) and conivaptan intervention in the management of 49 patients with case report I want to simplify that though conivaptan is not the first line of treatment for the euvolemic or hypervolemic hyponatraemia, but they can be used as a life saving drug for euvolemic or hypervolemic hyponatraemia, when all other common treatment modalities fail. One has to be very cautious while using vaptan group of drugs and also perform the strict serum sodium level monitoring.
was within normal limits. In the operating room (OR) patient's trachea was intubated with an 8.5 mm polyvinyl chloride (PVC) cuffed endotracheal tube (ETT) under general anesthesia using a videolaryngoscope and stylet. His Cormac Lehane (CL) grade was 3. The patient had a stable intraoperative course and after the procedure patient's trachea was extubated in OR and he was shifted to intensive care unit (ICU) for observation.
In the ICU after 6 hours the patient complained of respiratory distress. His blood oxygen saturation (SPO 2 ) dropped from 100-85% with no hypotension or auscultatory chest abnormality. There was no visible neck swelling, the suture line was intact without any leak from the incision site and surgical drain content was minimal. The arterial blood gas (ABG) of the patient revealed a pH of 7.20, partial pressure of oxygen in arterial blood (PaO 2 ) of 80 mm Hg and a partial pressure of carbon dioxide (PaCO 2 ) of 56 mm Hg. Assisted manual bag and mask ventilation
